Clinical Trials Browser

Phase NA × Recruiting × Meningeal Carcinomatosis × Clear all

NCT07398599 2026-04-23

Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study

Phase NA Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

NCT05746325 2026-04-02

Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer

Phase NA Recruiting

BreastCNSThoracic

Breast Neoplasms, Lung Neoplasms, Meningeal Carcinomatosis

NCT07348965 2026-04-02

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

Phase NA Recruiting

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06304441 2025-09-29

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Phase NA Recruiting

Meningeal Carcinomatosis

NCT05746754 2025-04-06

CSI ProLong

Phase NA Recruiting

Meningeal Carcinomatosis

NCT06643000 2025-03-06

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Phase NA Recruiting

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT05257967 2025-02-11

CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease

Phase NA Recruiting

Carcinoma, Non-Small-Cell Lung, Meningeal Neoplasms, Meningeal Carcinomatosis